Kimmy Nguyen: No financial relationships to disclose
This session will provide a comprehensive overview to enhance your ability to care for patients with community-acquired pneumonia (CAP). Understanding risk factors will ensure optimal initial treatment and recovery. Join experts in highlighting evidence-based guidelines and how the added arsenal of new therapeutics – Lefamulin and omadacycline – fall in line.
Learning Objectives:
Identify the organisms that cause CAP.
List the risk factors for drug-resistant S. pneuomoniae, MRSA, and Pseudomonas.
Describe new therapeutics for the treatment of community-acquired bacterial pneumonia.
Given a patient case, design an appropriate treatment plan based on current evidence.
